2023-03-28 09:04:01 ET
- Vaccitech ( NASDAQ: VACC ) is down 10% in premarket trading Tuesday despite posting top-line phase 1b/2a data on an immunotherapy for hepatitis B virus (HBV) that met primary and secondary endpoints.
- The open-label study examined VTP-300 in 55 people, with or without Opdivo (nivolumab), with chronic HBV.
- Results showed that VTP-300 led to meaningful, sustained reductions of Hepatitis B surface antigen (HBsAg) in patients with chronic HBV.
- There were no incidents of Grade 3 adverse events or product-related serious adverse events. However, transaminase flares occurred in two patients.
- The full results will be presented at the EASL Congress in June.
- Check out why Seeking Alpha's Quant Rating views Vaccitech ( VACC ) as a hold.
For further details see:
Vaccitech down 10% despite data on hepatitis B treatment